日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

N-glycosylated LTβR increases the Th17/Treg cell ratio in liver cancer by blocking RORC ubiquitination and FOXP3 transcription

N-糖基化的LTβR通过阻断RORC泛素化和FOXP3转录,增加肝癌中Th17/Treg细胞的比例。

Pan, Banglun; Yao, Yuxin; Wu, Hao; Ye, Dongjie; Zhang, Zhu; Zhang, Xinyu; Wang, Xiaoqian; Tang, Nanhong

RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer

RNASEH2C增强TRAF3IP1在溶酶体中降解RAI14,从而阻碍巨噬细胞抗原呈递并促进肝癌进展。

Pan, Banglun; Yu, Huahui; Lin, Zikun; Liu, Mengxin; Liu, Jiayu; Xu, Yiqing; Wu, Linqing; Zhang, Qiuyu; Wang, Zengbin

Intratumoral Brevibacillus parabrevis enhances antitumor immunity by inhibiting NK cell ferroptosis in hepatocellular carcinoma.

肿瘤内注射短芽孢杆菌可抑制肝细胞癌中NK细胞的铁死亡,从而增强抗肿瘤免疫力

Pan Banglun, Zhang Xiaoxia, Ye Dongjie, Yao Yuxin, Zhang Zhu, Luo Yue, Wu Hao, Wang Xiaoqian, Tang Nanhong

PPARα suppresses growth of hepatocellular carcinoma in a high-fat diet context by reducing neutrophil extracellular trap release

在高脂饮食环境下,PPARα通过减少中性粒细胞胞外陷阱的释放来抑制肝细胞癌的生长。

Pan, Banglun; Zhang, Zhu; Ye, Dongjie; Zhang, Xiaoxia; Yao, Yuxin; Luo, Yue; Hong, Haijie; Cai, Xinran; Chen, Yanling; Tang, Nanhong

New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity.

对 FXR 激动剂 Vonafexor 的新机制理解:通过促进抗肿瘤免疫诱导 HBV 阳性肝癌细胞的亚致死损伤

Pan Banglun, Chen Siyan, Zhang Zhu, Ye Dongjie, Zhang Xiaoxia, Yao Yuxin, Luo Yue, Wu Hao, Wang Xiaoqian, Tang Nanhong

SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.

SUMO化抑制剂通过重塑肝细胞癌临床前模型中的免疫微环境来激活抗肿瘤免疫。

Wang Zengbin, Pan Banglun, Su Lili, Yu Huahui, Wu Xiaoxuan, Yao Yuxin, Zhang Xiaoxia, Qiu Jiacheng, Tang Nanhong

Single-cell atlas reveals characteristic changes in intrahepatic HBV-specific leukocytes

单细胞图谱揭示肝内HBV特异性白细胞的特征性变化

Pan, Banglun; Wang, Zengbin; Chen, Rui; Zhang, Xiaoxia; Qiu, Jiacheng; Wu, Xiaoxuan; Yao, Yuxin; Luo, Yue; Wang, Xiaoqian; Tang, Nanhong

2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis

2,5-二甲基塞来昔布通过胃肠道菌群-AMPK-mTOR轴缓解肝细胞癌中的NK细胞和T细胞耗竭。

Pan, Banglun; Chen, Zhanfei; Zhang, Xiaoxia; Wang, Zengbin; Yao, Yuxin; Wu, Xiaoxuan; Qiu, Jiacheng; Lin, Hua; Yu, Liumin; Tu, Haijian; Tang, Nanhong

Correction to: A modified immune cell infiltration score achieves ideal stratification for CD8(+) T cell efficacy and immunotherapy benefit in hepatocellular carcinoma

更正:改良的免疫细胞浸润评分可实现对肝细胞癌中 CD8(+) T 细胞疗效和免疫治疗获益的理想分层

Pan, Banglun; Luo, Yue; Ye, Dongjie; Qiu, Jiacheng; Zhang, Xiaoxia; Wu, Xiaoxuan; Yao, Yuxin; Wang, Xiaoqian; Tang, Nanhong

A modified immune cell infiltration score achieves ideal stratification for CD8(+) T cell efficacy and immunotherapy benefit in hepatocellular carcinoma

改良的免疫细胞浸润评分可实现对肝细胞癌中 CD8(+) T 细胞疗效和免疫治疗获益的理想分层。

Pan, Banglun; Luo, Yue; Ye, Dongjie; Qiu, Jiacheng; Zhang, Xiaoxia; Wu, Xiaoxuan; Yao, Yuxin; Wang, Xiaoqian; Tang, Nanhong